{
  "sampleId": "ACTN01029999T",
  "type": "WGS",
  "date": {
    "year": 2021,
    "month": 2,
    "day": 23
  },
  "hasReliableQuality": true,
  "mutations": [
    {
      "gene": "TP53",
      "mutation": "exon 1"
    }
  ],
  "activatedGenes": [
    "ACT"
  ],
  "inactivatedGenes": [
    {
      "gene": "NF1",
      "hasBeenDeleted": false
    },
    {
      "gene": "RB1",
      "hasBeenDeleted": true
    }
  ],
  "amplifiedGenes": [
    "AMP"
  ],
  "wildtypeGenes": [
    "WILD"
  ],
  "fusions": [
    {
      "fiveGene": "five",
      "threeGene": "three"
    }
  ],
  "isMicrosatelliteUnstable": false,
  "isHomologousRepairDeficient": true,
  "tumorMutationalBurden": 4.32,
  "tumorMutationalLoad": 243,
  "actinTrialEvidence": [
    {
      "event": "High TML",
      "treatment": "Trial 1"
    },
    {
      "event": "HR deficiency",
      "treatment": "Trial 2"
    },
    {
      "event": "NF1 disruption",
      "treatment": "Trial 3"
    }
  ],
  "generalTrialSource": "trials",
  "generalTrialEvidence": [
    {
      "event": "High TML",
      "treatment": "Trial 1"
    }
  ],
  "generalEvidenceSource": "evidence",
  "generalResponsiveEvidence": [
    {
      "event": "High TML",
      "treatment": "Pembrolizumab"
    },
    {
      "event": "High TML",
      "treatment": "Nivolumab"
    }
  ],
  "generalResistanceEvidence": []
}
